Committee to Hold Landmark Hearing with Sackler Family Members and Purdue Pharma CEO on Role in Fueling Opioid Crisis with OxyContin

Dec 14, 2020
Press Release

Washington D.C. (Dec. 14, 2020)—On Thursday, Dec. 17, 2020, at 9:00 a.m., Rep. Carolyn B. Maloney, the Chairwoman of the Committee on Oversight and Reform, will hold a virtual hearing to examine the role of Purdue Pharma and members of the Sackler family in fueling the nationwide opioid epidemic for decades by pushing Purdue executives to flood the market with the highly addictive painkiller OxyContin.

 

In preparation for the hearing, Chairwoman Maloney issued a memo describing documents obtained by the Committee showing how members of the Sackler family used the OxyContin business to “stretch” Purdue’s financial targets and increase earnings.  The documents also reveal how Sackler family members pressured Purdue executives to grow market share for OxyContin and other opioids, including by targeting high-volume prescribers and pushing higher strength doses.

 

This will be one of the first times members of the Sackler family will testify in public under oath.  Purdue Pharma has generated more than $30 billion since bringing OxyContin to market in 1996, and the Sackler family has withdrawn more than $10 billion from the company.  Nearly 450,000 people in the United States have lost their lives to the opioid epidemic over the past two decades.

WHAT:  

 

Full Committee Hearing on “The Role of Purdue Pharma and the Sackler Family in the Opioid Epidemic”

 

WHEN:

Dec. 17, 2020, at 9:00 a.m. ET

 

WHO:    

 

David Sackler
Former Member of the Board of Directors (2012 to 2018)
Purdue Pharma L.P.

 

Dr. Kathe Sackler
Former Vice President and Member of the Board of Directors (1990 to 2018)
Purdue Pharma L.P.

 

Craig Landau
President and CEO
Purdue Pharma L.P.

WATCH:

A livestream will be available on YouTube and the Committee on Oversight and Reform website.

###

Issues: 
116th Congress